News

Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial
Key Takeaways Sarepta Therapeutics shares were down nearly 25% early Friday morning.The tumble followed a report that a third ...
Sarepta Didn’t Tell Investors About a Patient Death. Wall Street is Furious.
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
Fierce Biotech2h
3rd patient dies after receiving a Sarepta gene therapy
While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of ...
Sarepta's Setback Deepens With Another Gene Therapy Fatality
Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...
Southwest Journal5h
Breaking: Second Patient Death Prompts FDA Investigation of Sarepta’s Elevidys Gene Therapy
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
BioSpace4h
Sarepta Reports a Third Gene-Therapy Related Patient Death
The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute ...
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
STAT28m
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
Patient dies in Sarepta gene therapy trial, adding to safety concerns
The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
Becker's Hospital Review2h
Sarepta reports 3rd patient death after gene therapy treatment
A third patient has died from acute liver failure after receiving a gene therapy treatment from Sarepta Therapeutics, the biotech company confirmed to Bloomberg on July 18. The patient died while ...
Sarepta plunges after third patient death tied to gene therapy - report
Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...
Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring
Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...